- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00567372
POSTERIOR SUB-TENON'S Avastin
December 5, 2008 updated by: Asociación para Evitar la Ceguera en México
POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA
Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
7
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sandra Vera-Rodriguez, MD
- Phone Number: 1171 525510841400
- Email: retinamex@yahoo.com
Study Locations
-
-
DF
-
Mexico DF, DF, Mexico, 04030
- Recruiting
- Asociación Para Evitar la Ceguera en México
-
Contact:
- Yoko Burgoa, Lic
- Phone Number: 1171 525514841400
- Email: retinamex@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
macular volume
Time Frame: baseline, 3,6 and 12 weeks
|
baseline, 3,6 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
macular thickness
Time Frame: baseline,3,6 and 12 weeks
|
baseline,3,6 and 12 weeks
|
best corrected visual acuity
Time Frame: baseline, 3,6 and 12 weeks
|
baseline, 3,6 and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sandra Vera, MD, Asociación Para Evitar la Ceguera en México
- Principal Investigator: Hugo Quiroz-Mercado, MD, Denver Health Medical Center
- Principal Investigator: Adai Pérez-Montesinos, MD, Asociación Para Evitar la Ceguera en México
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Anticipated)
November 1, 2008
Study Completion (Anticipated)
June 1, 2009
Study Registration Dates
First Submitted
November 30, 2007
First Submitted That Met QC Criteria
December 3, 2007
First Posted (Estimate)
December 4, 2007
Study Record Updates
Last Update Posted (Estimate)
December 8, 2008
Last Update Submitted That Met QC Criteria
December 5, 2008
Last Verified
December 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00922
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Diabetic Macular Edema
-
Shahid Beheshti University of Medical SciencesUnknownDiffuse Diabetic Macular EdemaIran, Islamic Republic of
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Military Institute of Medicine, PolandUnknown
-
iCo Therapeutics Inc.CompletedDiffuse Diabetic Macular EdemaUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknown* Diffuse Diabetic Macular EdemaMexico
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
Clinical Trials on bevacizumab (Sub-tenon´s injection)
-
Massachusetts Eye and Ear InfirmaryRegeneron PharmaceuticalsRecruiting
-
Stanford UniversityWithdrawn
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
JDP Therapeutics, Inc.Algorithme Pharma IncCompleted
-
Wills EyeCompleted
-
Sun Pharmaceutical Industries LimitedRecruitingPsoriatic ArthritisUnited States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of
-
University of Sao PauloCompletedDiabetic Retinopathy | Retinal Disease | MaculopathyBrazil
-
Cairo UniversityRecruitingAnesthesia, Local | Strabismus | Pediatric ALL | OphthalmopathyEgypt
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedCervical Cancer | Glioblastoma | Ovarian Cancer | Lung Cancer | Rectal CancerChina
-
Assistance Publique - Hôpitaux de ParisCompleted